CL2023002841A1 - Método para producir spesolimab - Google Patents

Método para producir spesolimab

Info

Publication number
CL2023002841A1
CL2023002841A1 CL2023002841A CL2023002841A CL2023002841A1 CL 2023002841 A1 CL2023002841 A1 CL 2023002841A1 CL 2023002841 A CL2023002841 A CL 2023002841A CL 2023002841 A CL2023002841 A CL 2023002841A CL 2023002841 A1 CL2023002841 A1 CL 2023002841A1
Authority
CL
Chile
Prior art keywords
spesolimab
relates
present
species
producing
Prior art date
Application number
CL2023002841A
Other languages
English (en)
Inventor
Wucherpfennig Thomas
Lippmann Rico
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2023002841A1 publication Critical patent/CL2023002841A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un método para producir el anticuerpo anti-IL36R spesolimab. Más específicamente, presente invención se refiere a un método para producir spesolimab con un medio de cultivo celular libre de suero en un cultivo alimentado por lotes en la presencia de concentraciones reducidas de cobre y concentraciones aumentadas de hierro. Además, la presente invención se refiere a una composición que comprende niveles bajos de especies básicas de spesolimab y/o niveles bajos de especies de spesolimab con estructuras con alta manosa.
CL2023002841A 2021-05-03 2023-09-25 Método para producir spesolimab CL2023002841A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21171881 2021-05-03

Publications (1)

Publication Number Publication Date
CL2023002841A1 true CL2023002841A1 (es) 2024-03-22

Family

ID=75787012

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002841A CL2023002841A1 (es) 2021-05-03 2023-09-25 Método para producir spesolimab

Country Status (11)

Country Link
US (1) US20220356258A1 (es)
EP (1) EP4334356A1 (es)
JP (1) JP2024517784A (es)
KR (1) KR20240004718A (es)
CN (1) CN117222668A (es)
AU (1) AU2022269799A1 (es)
BR (1) BR112023017717A2 (es)
CA (1) CA3218684A1 (es)
CL (1) CL2023002841A1 (es)
TW (1) TW202309087A (es)
WO (1) WO2022233770A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022015920A1 (en) * 2020-07-17 2022-01-20 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for the treatment of neutrophilic dermatoses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047380A2 (en) * 2004-10-22 2006-05-04 Amgen, Inc. Method and media for single cell serum-fee culture of cho cells
US8911964B2 (en) * 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
DK2780373T3 (da) * 2011-11-16 2019-11-04 Boehringer Ingelheim Int Anti-IL-36R-antistoffer
BR112015022529A2 (pt) * 2013-03-15 2017-07-18 Genentech Inc meios de cultura de células e processos de produção de anticorpo
JP2017500017A (ja) * 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
US11505784B2 (en) 2015-04-01 2022-11-22 Boehringer Ingelheim International Gmbh Cell culture medium
US20200207862A1 (en) * 2018-12-27 2020-07-02 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of palmoplantar pustulosis

Also Published As

Publication number Publication date
BR112023017717A2 (pt) 2024-01-09
TW202309087A (zh) 2023-03-01
US20220356258A1 (en) 2022-11-10
AU2022269799A1 (en) 2023-09-14
KR20240004718A (ko) 2024-01-11
WO2022233770A1 (en) 2022-11-10
CN117222668A (zh) 2023-12-12
EP4334356A1 (en) 2024-03-13
JP2024517784A (ja) 2024-04-23
CA3218684A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
CL2023002841A1 (es) Método para producir spesolimab
AR121142A1 (es) Microorganismo que comprende un lyse mutado y método de producción de un l-aminoácido que lo utiliza
DE602004027355D1 (de) Methode und zusammensetzung für sekundärölforderung
BR112013002005A2 (pt) estrutura de segurança, documento de segurança e processo para autenticar um documento de segurança e uma da primeira e segunda composição da estrutura de segurança do documento formando pelo menos um padrão
CO6690745A2 (es) Método para producir el factor von willebrand (vwf) de alto peso molecular recombinante en cultivo celular
ECSP15030861A (es) Copolímeros hidrosolubles hidrofóbicamente asociados con nuevos monómeros hidrofóbicamente asociados
BR112013002202A2 (pt) (met)acrilato de polialquila para melhorar as propriedades de óleos lubrificantes
BRPI0612409B8 (pt) composições de tensoativos à base de ácido peroxicarboxílico e método de reduzir a população de microorganismos em um objeto
AR057785A1 (es) Tablero de tabique con propiedades antifungicas y metodo para hacer el mismo
AR077115A1 (es) Produccion de isopreno usando las vias de mevalonato (mva) y la de no mevalonato (dxp)
NI200800111A (es) Método de producción proteica utilizando compuestos anti-senescencia
UY36590A (es) Uso de deshidrogenasa alcoholica transformadora de un tricoteceno,metodo para la transformación de tricotecenos y aditivo transformador de tricotecenos
BRPI0612781B8 (pt) uso de um meio de cultura livre de soro para reduzir os níveis de formas oxidadas de uma gonadotrofina dimérica recombinante durante seu processo de fabricação
BRPI0416959A (pt) composição, artigo, e, método para conferir repelência e anti-sujeira a um substrato, tendo uma ou mais superfìcies
DE60232322D1 (de) Verfahren
MX2022010211A (es) Composiciones de hormigon mejoradas y metodos para producir las mismas.
AR078716A1 (es) Anticuerpos antihepsina y metodos para su uso
AR104895A1 (es) Conjugados fluorescentes
CL2023002712A1 (es) Composiciones cementicias y métodos relacionados
BR112021024852A2 (pt) Métodos de cultura de célula e composições para produção de anticorpo
DE60125403D1 (de) Verfahren zur verbesserung der pigmentfluoreszenz
AR078092A1 (es) Recubrimiento auto-lubricante y metodo para producirlo
BR112022014908A2 (pt) Métodos de decodificação de vídeo e dispositivo de decodificação de vídeo
MX2021012610A (es) Composiciones y metodos para la estabilizacion de micro-arn.
BR112012026765A2 (pt) processo para fabricação de uma composição detergente líquida